Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Is Eli Lilly a good stock to buy on the dip ... Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat Alzheimer's disease. Intended for early-stage patients ...

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading ... Major contributors to 2025 revenues will be new LLY medicines such as Jaypirca, Ebglyss, Omvoh and Kisunla, approvals of new ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly's stock price finished Jan. 16 down 21 ... Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat Alzheimer's disease. Intended for early-stage ...